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Abstract: A practical, integrated and versatile U-4CR-based assembly of 1,4-
benzodiazepin-2-ones exhibiting functional, skeletal and stereochemically diverse 
substitution patterns is described. By virtue of its convergence, atom economy and 
bond-forming efficiency herein documented methodology exemplify the reconciliation 
of structural complexity and experimental simplicity in the context of medicinal 
chemistry projects. 
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Introduction 
Extensively employed as therapeutics since the early 1960s 1,4-benzodiazepin-
2-ones (BZDs) embody the archetypical privileged structure,
1
 a concept coined by 
Evans in the late 1980s
2
 and that constitute a fruitful strategy to improve the low hit 
rates usually experienced during high-throughput screening campaigns. Whereas BZD 
scaffolds are recurrent templates in the context of CNS therapies (being extensively 
prescribed as sedatives, anxiolytics, anticonvulsants or muscle relaxants),
3
 the 
continuous appearance of reports describing novel pharmacological activities (e.g. 
antitumor, anti-HIV, antiarrhythmic, antitrypanosomal)
4
 unequivocally corroborate the 
ability of BZDs to modulate biological targets beyond CNS targets (Figure 1). 
 
 
Figure 1. Representative drugs and bioactive compounds derived from the 1,4-
benzodiazepin-2-one scaffold. 
 
The BZD´s pharmacogenicity profile heavily relies on its constrained peptide 
mimic nature,
3,4
 which dictates the geometry of the heterocyclic core and its appended 
functional groups, thus modulating the structural parameters ultimately governing 
ligand/receptor interactions. In such a context it should emphasized that BZDs exist in a 
boat conformation, which confers intrinsic chirality to the heterocyclic core even in the 
absence of stereogenic carbons.
5
 The barrier for racemization between (M)- and (P)- 
enantiomers is known to be low,
5,6 
unless they exhibit a single substituent at C3 -which 
is stabilized at the pseudoequatorial position- or a relatively large substituent at position 
1.
7
 Consequently, the stereochemical diversity in BZD´s collections can be easily 
expanded by combining the chirality of the heterocyclic core with stereocenters at C3 or 
by introduction of chiral side-chains at position 1 of the framework. 
 
 
Figure 2. (P) and (M) conformational enantiomers of 1,4-benzodiazepin-2-ones. 
 
In addition to the bioactivity issues, the versatility of a privileged scaffold is 
heavily dependent on two key factors: it’s synthetic feasibility and its ability to be 
decorated and/or reinterpreted according the specific requirements of distinct biological 
targets. Therefore, the implementation of concise and efficient synthetic methodologies 
providing integrated access to privileged molecular frameworks eliciting functional, 
skeletal as well as stereochemical diversity, while enabling the reconciliation of the 
molecular complexity with experimental simplicity, constitutes a highly appreciated 
goal within the competitive environment of drug discovery. Despite the plethora of 
synthetic methods targeting BZDs,
8
 established approaches consists in multistep linear 
pathways; where diversity elements are usually early introduced. Epimerization is often 
an issue; particularly during the subsequent functionalization stages of the heterocycle.
9
 
A valuable incorporation to the compendium of preparative methods targeting BZDs 
includes multicomponent reactions (MCR);
10
 which have emerged as a tailored 
synthetic paradigm in drug discovery. Perhaps the most powerful MCR-assisted method 
for generating BZD libraries
11
 involves the Ugi four-component reaction (U–4CR).12 
Whereas this strategy has provided examples of elegant access to diverse BZD 
scaffolds,
11,12
 most described protocols still require several synthetic steps and/or 
structurally elaborate precursors; thereby hampering its extensive application in 
medicinal chemistry programs. Additionally, the development of modular MCR-based 
approaches providing collections of privileged molecular frameworks in enantio- or 
diastero- pure fashion remains a highly elusive challenge.
11
 We herein document a 
conceptually simple and modular U–4CR–based approach that provides an integrated 
access to functional, skeletal and stereochemically diverse chemotypes derived of the 
pharmacologically useful 1,4-bezodiazepin-2-one framework. 
 
Results and Discussion 
In the frame of a medicinal chemistry program series of 1,4-benzodiazepin-2-
ones, simultaneously incorporating functionalized alkyl chains at N1 and concise 
chemical and stereochemical substitution patterns at position 3 of the heterocyclic core, 
were required. Being aware of the limitations of classical synthetic approaches to access 
the targeted chemotypes, we decided to assess the feasibility of a MCR-based approach. 
It was envisioned (Scheme 1) that the U-4CR reaction employing 2-
aminophenylketones (1) as amine input, in combination with N-Boc protected 
aminoacids (2), isocyanides (3) and a carbonyl partner (4), would afford the 
corresponding Ugi adducts (5), which upon removal of the protecting group would 
undergo an intramolecular cyclization to provide the targeted BZDs (Scheme 1). The 
feasibility of the proposed approach relies heavily on the reactivity of the carbonyl 
moiety of the starting 2-aminophenylketone (1) when coexisting with alternative 
carbonyl compounds during the U–4CR. 
 Scheme 1. Retrosynthetic analysis to BZD derivatives 6–9 through U–4CR. 
 
While a few reports have exemplified the use of aminoketones (1) toward U-
4CR,
13
 to the best of our knowledge, these works have employed aldehydes as carbonyl 
components; remaining unexplored the reaction outcome of this transformation with 
ketones. Two recent papers have described Ugi-based benzodiazepine synthesis 
conceptually related to herein document approach. The first study, published by Torroba 
et al. in 2010,
14
 documents an U-4CR that employs 2-aminobenzophenone and (S)-2-
azido-3-phenylpropanoic acid as key components (in combination with 
cyclohexylisocyanide and three substituted benzaldehydes); thus generating Ugi adducts 
that were subsequently cyclized under the Staudinger/aza-Wittig reaction conditions. 
This elegant approach is, notwithstanding, strongly limited by the scarce availability of 
functional and stereochemical diverse 2-azidopropanoic acids. This paper inspired the 
design of the herein documented pathway (Scheme 1). As observed, it follows the Ugi-
deprotect-Cyclize (UDC) strategy and capitalizes the availability functional and 
stereochemical diversity of N-Boc protected aminoacids (2). During the practical 
implementation of our study a communication
15
 described several novel U-4CR 
approaches to 1,4-benzodiazepine scaffolds; one of them briefly exploring herein 
documented approach. Since our exhaustive examination of the transformation reveals 
novel reactivity facets and expand method´s scope, but also provides novel 1,4-
benzodiazepin-2-ones chemotypes featuring unexplored functional, skeletal and 
stereochemical substitution patterns (Figure 2), we decided to present our results. 
  
 
Figure 3. Structure and numbering of 1,4-benzodiazepin-2-one chemotypes (6-9) 
assembled through the Ugi–based approach herein described. 
 
 
 
 
 
 
 
As a proof of concept (Scheme 2) 2-aminobenzophenone (1a) and 2-
aminoacetophenone (1b) were selected as model amine substrates for the Ugi reaction, 
in combination with glycine Boc (2a) and benzyl isocyanide (3a). Whit the aim to 
exhaustively evaluate the chemoselectivity profile of the transformation, and 
consequentially its robustness and potential contribution in terms of chemical diversity, 
aldehydes [e.g. formaldehyde (4a), butyraldehyde (4b) and benzaldehyde (4c)] but also 
ketones [e.g. propanone (4d) and cyclohexanone (4e)] were employed as reactive inputs 
(Scheme 2). The selected substrates were submitted to the standard conditions of the 
Ugi condensation in methanol (Scheme 2). Analysis of reaction behaviour for model 
substrates revealed that transformations are successful regardless of the steric hindering 
present at either the amine (1) or the carbonylic partners (4); with more than 85% of 1 
consumed after 36 h in most experiments (independently of the use of aldehyde or 
ketone). The intermediancy of the α-acylamino amides 5 was unequivocally confirmed 
by the spectroscopic methods. It was gratifying to find that, upon reaction quenching 
and subsequent cleavage of the protecting group, Ugi adducts are readily transformed; 
triggering BZDs 6 in a two-step one-pot fashion with overall yields ranging 46-77% 
(Scheme 2). Among a variety of tested reagents to remove the BOC group, 20% TFA in 
DCE at 60ºC provided an efficient cleavage while simultaneously promoting mild 
cyclization in short reaction times (0.5-1 h). With the aim to evaluate the robustness of 
the method, the reactivity of other isocyanides [e.g. cyclohexyl (3b) or tert-butyl (3c)] 
was preliminarily tested; thus generating the 1,4-benzodiazepin-2-ones 6k-t. In 
concordance with previous observations,
16
 the use of polystyrene supported p-
toluenesulfonic acid once finished the U-4CR, in addition to remove traces of the 
remaining isocyanide, simultaneously scavenges the unreacted amine (1); thus 
simplifying the purification stage. 
Scheme 2. Ugi-Based Assembly of 1,4-benzodiazepin-2-ones 6. 
 
 
  
 
 
 
As observed (Scheme 2), both aldehydes (aliphatic or aromatic) and ketones 
(acyclic and cyclic) were found to be good substrates, with the transformation 
exhibiting complete chemoselectivity. It should be highlighted that the herein 
documented strategy enables the straightforward introduction of challenging residues on 
the exocyclic acetamide linkage under neutral conditions, as represented for 2,2-
dimethyl derivatives (6d, 6i, 6n and 6s) and particularly for the cyclohexyl analogues 
(6e, 6j and 6t). In addition to validate the feasibility of the proposed pathway, the 
results included in scheme 2 provide a preliminary assessment of the exploratory power 
of this conceptual and experimentally simple strategy. It should be noticed that herein 
documented strategy assemble BZDs 6 in a one-pot procedure that involves the 
formation of six new bonds; thus exhibiting outstanding bond-forming efficiency and 
step economy. 
 
Analysis of the NMR spectra of compounds 6a-t enables to observe that 
exchange between the two boat enantiomeric conformations P and M is slow in the 
NMR chemical shift time scale, as previously observed for BZDs with bulky 
substituents on N1.
7
 This is assessed by observing the C3 protons resonances in the 
1
H-
NMR spectrum. At room temperature the H3 protons are observed as two well 
separated doublets (δ Hax ~3.5 ppm vs. δ Heq ~4.5 ppm, |2JHH| = 10.5 - 12.5 Hz). The 
strong shielding of the pseudoaxial proton Hax is caused by the phenyl ring of the BZDs 
skeleton. When prochiral aldehydes were used in the Ugi reaction (e.g. 4b and 4c) a 
new stereocenter is introduced in the side chain at position 1’ and the (P) and (M) boat 
conformations become diastereomeric (Figure 4). In the 
1
H-NMR spectra of these 
compounds (6b, 6c, 6g, 6h, 6l, 6m, 6o, 6q, 6r), resonances corresponding to each 
diastereomeric pair of enantiomers —(P,S)/(M,R) vs (P,R)/(M,S)— can be seen, with 
diastereomeric ratios ranging from 1:2 to 1:5. 
 Figure 4. Diastereomeric 1,4-benzodiazepin-2-one chemotypes assembled. 
 
Once the feasibility of the proposed method was established for glycine Boc 
(Scheme 2), and having identified optimal experimental conditions to perform the Ugi–
deprotect–cyclize (UDC) sequence, the robustness and scope of the developed 
methodology was assessed substituting glycine-Boc (2a) by a set of assorted protected 
aminoacids (2b-g) as key reactive precursors (Scheme 3). The study capitalizes the 
excellent commercial availability of enantiopure Boc protected aminoacids (2) to 
introduce functional and stereochemical diversity at position 3 of the heterocyclic 
framework. Firstly we focused on the generation of collections of BZDs bearing a 
stereocenter at C3 (Compounds 7, Scheme 3). With this aim amines 1a-b, assorted 
isocyanides (3) and either formaldehyde (4a) or a symmetric ketone (4d-e) were 
combined in the Ugi reaction with a set of structural and stereochemically diverse 
enantiopure Boc-protected aminoacids (2b-g). We were pleased to observe that only 
slight modifications of the previously optimized experimental protocol (Scheme 3) were 
required to verify the transformation of reactive partners of the U-4CR in the α-
acylamino amides 5. A slight excess (1.3 equivalents) of the amine input (1) and longer 
reaction times (48-72 h) were usually required to achieve superior conversion ratios of 
the U–4CR, while maintaining mild experimental conditions. 
 
Scheme 3. U-4CR-based assembly of enantiopure BZDs incorporating functional and 
stereochemically diverse groups at position 3. 
 
  
 
 
 
As for the model systems, smooth cleavage of the protecting group on the Ugi 
adducts (5) employing TFA (DCE/60ºC) afforded BZDs 7 in satisfactory yields (44-
71%). It was verified that during the synthesis no occurs racemization at the 
stereocenter (ee > 95%), as determined by chiral-stationary HPLC analysis. A rapid 
inspection of scheme 3 provides a preliminary assessment of reaction´s scope, which 
generates 1,4-benzodiazepin-2-one collections incorporating 4 points of diversity. As 
observed, it encompasses use of aliphatic as well as aromatic inputs of all variable 
components, being not influenced by the electronic and steric variations of the reacting 
substrates. Significant structural and stereochemical diversity is successfully provided 
by the aminoacid partner (2), as exemplified by a range of diverse residues (including 
proteinogenic or synthetic aminoacids); some of them bearing challenging residues (e.g. 
compounds 7i and 7j). The NMR data of this series reveals that, for steric reasons, the 
substituent at C3 is placed preferentially at the pseudoequatorial position (Figure 5). 
Hence,  the 3S and 3R enantiomers will be locked in the M and P conformations 
respectively and indeed, the 
1
H-NMR of all compounds 7 showed the resonances of a 
single diastereoisomer, with the H3 resonance around 3.5 ppm, that is a clear indication 
of its pseudoaxial position. Since a single set of signals is observed in the 
1
H-NMR 
spectrum, it means that the single enantiomers (M,3S) and (P,3R) were obtained when 
the (S)- and (R)-aminoacids were respectively used. 
 
 
Figure 5. Preferred conformations of (P,3R) and (M,3S) enantiomers of 3-substituted 
benzodiazepines. 
The structural assignment within the series (see supporting information) was 
complemented by X-ray crystallography data obtained on monocrystals of two 
representative compounds (Compound 7p and 7u, Figure 6).
17
 
 
 
 
Figure 6. Ortep plot showing the crystal structure and atomic numbering scheme 
for compounds 7p and 7u. 
 
The success achieved on previous series led us to evaluate the utilization of 
prochiral carbonyl components (4b-c), which will engender the exocyclic stereocenter 
formed during the U–4CR (Scheme 4). Butyraldehyde (4b) and benzaldehyde (4c) were 
employed in combination with enantiopure N-Boc protected aminoacids (2b-g) and the 
other reactive partners (Scheme 4). These substrates were submitted to stirring at room 
temperature in methanol affording the corresponding diastereomeric Ugi adducts (5) that 
were directly transformed into BZDs 8 following the Boc-cleavage-cyclization sequence 
induced by TFA (Scheme 4). The obtained compounds were purified (by either 
recrystallization or chromatography) and characterized by spectroscopic and analytical 
techniques; thus verifying the isolation of desired BZDs (8) as 1:1 diastereomeric 
mixtures. Gratifyingly, the exhaustive scrutiny of solvent mixtures enabled to separate a 
set of representative diastereoisomers pairs (8a-g), employing conventional 
chromatographic methods. Comparative chiral HPLC analysis of pure samples of the 
diastereomeric mixture and the optically pure diastereoisomers unequivocally confirmed 
the optical purity of both pairs. 
 
Scheme 4. Ugi–Based Assembly of diastereoisomeric BZDs 8 
 
 
 
Due to the difficulties to assign the configuration of the BZDs of the series 8, and 
taking into account that important changes in chemical shifts were observed between the 
diasteroisomeric pairs, we decided to resort to DFT computations as a procedure for the 
assignment of the relative configurations of the obtained diasteroisomers 8. In the last 
decade DFT ab initio chemical shift computations
18
 have gradually gained importance 
among the toolbox used by organic chemists for configurational and conformational 
analysis through NMR in solution. These studies can be carried out at very affordable 
computer times, and with enough accuracy, can be successfully employed to distinguish 
diastereoisomeric structures; even in the presence of conformational flexibility.
19
 In the 
case of flexible molecules, like the ones treated herein, the determination of the 
configuration is commonly coupled to the determination of the preferred conformational 
state. We have therefore explored the conformational space of four representative 
stereoisomers (8b1, 8b2 and 8d1, 8d2) by means of molecular mechanics Monte Carlo 
calculations. The obtained molecular mechanics structures were refined at the DFT RI-
OPBE level (See experimental section for detailed computational procedures). In 
accordance with NMR observations the BZD ring is conformationally locked into the 
boat conformation where the alkyl group at C3 is placed into the equatorial position. 
Computations show that the conformation of the N1-side chain is dictated by the 
formation of an intramolecular hydrogen bond between the azepine carbonyl group at C2 
and the NH group, which build a new seven membered ring. The two rings adopt a 
convex-concave disposition as the lowest energy form. Thus, the basal conformation for 
the (3S,10R) isomer corresponds to a pseudo-axial disposition of the side-chain phenyl 
group, but a pseudo-equatorial disposition in the case of the (3S,10S) form (Figure 7). 
The presence of an intramolecular hydrogen bond between the NH and carbonyl C2 was 
confirmed experimentally by variable temperature 
1
H-NMR in CDCl3 solution, that 
yielded temperature coefficients of –1.4 ppb/K for compounds 8d1 and 8d2. Typically, 
values more positive than –4.5 ppb/K are considered to support intramolecular H bond.20 
 
 
Figure 7. Top: DFT lowest energy conformations for (P,3R,10S) -8b1 and 
(P,3S,10R)-8b2. Bottom: Selected experimental (bold) vs. computed 
1
H chemical 
shifts of compounds 8b (middle) and 8d (bottom). 
 
1
H Chemical shieldings were computed at the DFT/IGLO OPBE/pcS-1 level for 
the lowest energy DFT optimized conformation of each diastereoisomer. The computed 
shieldings were transformed into chemical shifts by computing shieldings for the 
tetramethysilane molecule at the same level of theory. The most remarkable difference 
between the diastereoisomers is a strong change of the H10 resonance (  = 0.38 ppm 
and 0.88 ppm in 8b and 8d, respectively) in the 
1
H NMR spectra. This agrees with the 
DFT computations, that predicted deshielding values  = 0.39 ppm for (P,3R10S)-8b1 
vs (P,3R10R)-8b2, and  =1.00 ppm for (M,3S10R)-8d2 vs. (M,3S10S)-8d1. The NMR 
structural assignment within the series was corroborated by X-ray crystallography data 
obtained on a monocrystal of the diastereoisomer 8d2 (Figure 7).
21 
Note that in the crystal 
the intramolecular hydrogen bond is no longer present and intermolecular H-bond 
contacts appear instead. As previously mentioned, the substituent at C3 is preferentially 
located on the pseudoequatorial position, fixing the BZD core either at the (M,3S) or at 
the (P,3R) conformation. The isopropyl group adopts an antiperiplanar  conformation 
around the H–C–C–H torsion angle. This is also the case in solution as evidenced by a 
vicinal coupling between H3 and the isopropyl methine proton  of ~10 Hz in both isomers 
8d1 and 8d2.  
 
Figure 7. Ortep plot showing the crystal structure and atomic numbering  
scheme for compound 8d2 
 
 
As significant differences in the deshielding of the H10 resonance is a common 
feature of all herein synthesized diastereomeric pairs, we used this diagnostic signal to 
assign the configuration at C10 for compounds 8. Supported by the DFT calculations 
performed (for 8b1, 8b2, 8d1, 8d2), as well as by the X-ray diffraction analysis of 8d2, 
we assumed that the signal for H10 is more deshielded for (P,3R,10R) or (M,3S,10S) 
compound than for the corresponding (P,3R,10S) or (M,3S,10R) diastereoisomer. The 
assignment of the relative configuration at C10 of compounds 8 is presented in Table 1. 
Table 1: Assignment of C10 configuration on compounds 8 based on chemical shifts of 
H10. 
 
δ H10 in ppm / (Configuration) 
Diastereoisomer 1 Diastereoisomer 2 
5.68 / (P,3R,10S)-8a1 6.12 / (P,3R,10R)-8a2 
5.58 / (P,3R,10S)-8b1
a 
6.00/ (P,3R,10R)-8b2
a 
4.16 / (P,3R,10S)-8c1 5.09 / (P,3R,10R)-8c2 
5.05 / (M,3S,10S)-8d1
a 
4.17 / (M,3S,10R)-8d2
a,b 
4.18 / (P,3R,10S)-8e1 4.99 / (P,3R,10R)-8e2 
5.80 / (P,3R,10S)-8f1 6.16/ (P,3R,10R)-8f2 
6.27 / (M,3S,10S)-8g1 5.79 / (M,3S,10R)-8g2 
a
Predicted by DFT calculations. 
b
Confirmed by DRX 
 
To further challenge the robustness and versatility of the herein documented U-
4CR–based strategy, the assembly of BZDs exhibiting challenging substitution patterns 
at position 3 of the heterocyclic backbone was briefly explored (Scheme 5). It should be 
noted that, although large and diverse BZD libraries are available; 1,4-benzodiazepin-2-
ones featuring quaternary centres at position 3, and particularly spiranic compounds 
derived of this heterocyclic core, have been only rarely described.
5,6
 To the best of our 
knowledge, there are not precedents of 1,4-Benzodiazepin-2-ones featuring the 
substitution patterns herein documented (e.g. 3,3-disubstituted and functionalized at 
position 1, compounds 9); with its close analogues requiring lineal multistep synthetic 
strategies that require harsh experimental conditions not compatible with functionalized 
frameworks.
5,6
 Since the introduction of these substitution patterns is expected to 
profoundly modify the structural features of the heterocyclic core, and accordingly its 
pharmacological profile, novel methods providing a rapid and experimentally simple 
entry to these chemotypes remains a highly pursued methodological challenge. 
 
Two sterically hindering N-Boc protected carboxylic acids [e.g. 2-((tert-
butoxycarbonyl)amino)-2-methylpropanoic acid (2i) and 1-((tert-butoxycarbonyl)ami-
no)cyclopentanecarboxylic acid (2j)] were selected as model substrates to study the 
proposed U–4CR sequence (Scheme 5); in combination with the precursors employed 
along this study [e.g.  amines 1a-b, tertbutyl isocyanide (3c) and the four carbonyl 
components (4a-d)]. The information contained in scheme 5 reveals novel reactivity 
facets of herein described Ugi–based BZDs assembly, while exemplify its contribution 
in terms of rapid access to complex and hitherto unexplored diversity spaces. The 
preliminary screening of the transformation revealed a significant decreasing on the 
reactivity profile and scope respect previous series (Schemes 2-4), with reaction 
behaviour being highly dependent of the starting carbonyl compound (Scheme 5). Thus, 
aldehydes evaluated (formaldehyde, butyraldehyde and benzaldehyde) smoothly 
underwent the U–4CR, albeit with a reduced efficiency respect previous series, 
affording the corresponding Ugi adducts that were subsequently cyclized (Scheme5). It 
should be noted that isolated yields of BZDs 9 range from satisfactory to moderate (35-
52%), clearly correlating with the steric hindering within the starting aldehyde (Scheme 
5). In a clear contrast, the U–4CR employing ketones (propanone and cyclohexanone) 
failed to provide the desired Ugi adducts (Scheme 5); exclusively affording keto 
aminoacetamides 10 (43-66%) and variable amounts of the unreacted precursors. All 
attempts to improve these results, by varying reagents ratio, solvents (EtOH, 
CF3CH2OH, toluene, DCM) temperatures (45, 60ºC) did not modify reaction outcome; 
at either the qualitative (compound isolated) or quantitative (yield) level. With the 
exception of U–4CR that employ formaldehyde as carbonyl component, all 
transformations employing 2i and 2j afforded variable amounts of substituted keto 
aminoacetamides 10; which becomes the only isolated reaction product when 
employing ketones. Such an experimental outcome, not observed for the less congested 
aminoacids (Schemes 2-5), clearly reflects the impossibility of the substituted 
carboxylic acid (carboxylate to be more precise) to attack steric hindering nitrilium ion 
intermediates. It should be noted that, although the steric factors showed to exert a key 
role on reaction behaviour, the substituent present in the starting amine (R1 = Me or Ph) 
seems do not affect reaction´s viability (Scheme 5). 
 
Scheme 5. Ugi–Based Assembly of 1,4-benzodiazepin-2-ones featuring quaternary 
centres at C3.  
 
 
 
 
 
Although it is premature to propose a detailed mechanism at this stage; a 
plausible mechanistic proposal, consistent with the above-described experimental 
results, is presented in Scheme 6. The overall transformation would start with imine 
formation (11) and its subsequent protonation, thus generating the iminium ion 12; 
which rapidly undergoes nucleophilic addition of the isocyanide to generate the highly 
reactive nitrilium 13. At this point of the transformation the steric hindering on the 
nitrilium ion intermediate (13) govern the reaction outcome. Thus, less congested 
nitrilium adducts (R4 = R5 = H) follow the normal course of the U–4CR [e.g. 
carboxylate insertion to give 14 and then Mum rearrangement] affording the expected 
Ugi adducts (15), that upon acid-mediated cleavage generate the targeted BZDs (9). In 
contrast, for nitrilium ions 13 derived of butyraldehyde, benzaldehyde or ketones the 
reaction behaviour heavily depends of its substitution pattern at the acetamide linkage. 
The superior steric hindering in these intermediates partially, or completely (for those 
derived of ketones), prevents the nucleophilc addition of the carboxylate ion; 
accordingly a water molecule could intercept the reactive nitrilium intermediate (17) to 
afford the isolated keto aminoacetamides 10. 
 Scheme 6. Mechanistic proposal for the Ugi–Based Assembly of 3,3-substituted 1,4-
benzodiazepin-2-ones 
 
In summary, we have documented a convergent approach that enables the 
straightforward assembly of 1,4-benzodiazepin-2-ones exhibiting high skeletal, 
functional and stereochemical diversity. This versatile integrated U–4CR-based 
strategy, that exhibits high bond-forming efficiency as well as structure and step 
economies, not requires advanced intermediates, anhydrous solvents or transition metal 
catalysts; thus exemplifying the reconciliation of molecular complexity and functional 
diversity with experimental simplicity. Further work is in progress in our laboratories to 
apply this method to the synthesis of novel BZD derivatives and complete the 
pharmacological evaluation of herein documented library. 
 
 
 
Experimental Section 
Commercially available starting materials and reagents were purchased and used 
without further purification from freshly opened containers. All solvents were purified 
and dried by standard methods. Organic extracts were dried with anhydrous sodium 
sulphate. The reactions were monitored by TLC and purified compounds each showed a 
single spot. Unless stated otherwise, UV light and/or iodine vapour were used for the 
detection of compounds. The synthesis and purification of all compounds were 
accomplished using the equipment routinely available in organic chemistry laboratories. 
Most of the preparative experiments were performed in coated vials on an organic 
synthesiser with orbital stirring. Purification of isolated products was carried out by 
recrystallization or chromatographic methods. Reported yields correspond to the mean 
of two synthetic experiments. Compounds were routinely characterised by 
spectroscopic and analytical methods. Melting points were determined on a melting 
point apparatus and are uncorrected. The chemical structures of the obtained compounds 
were characterized by nuclear magnetic resonance spectroscopy (
1
H and 
13
C) and high-
resolution mass spectra (HRMS). Unless otherwise quoted, NMR spectra were recorded 
in CDCl3. Chemical shifts are given as  values against tetramethylsilane as internal 
standard and J values are given in Hz. All NMR experiments were carried out at 298 K 
on a Bruker Avance 600 spectrometer operating at 600.13 MHz for 
1
H, 150.90 MHz for 
13
C and 90.56 MHz for 
2
H, equipped with a triple resonance inverse (TXI) room 
temperature probe with Z-only gradients. 
1
H and 
13
C resonances of (SR)602 and (SS)-
602 in CDCl3 solutions were assigned from ge-HSQC, ge-HMBC and ge-COSY 
experiments. Shifts were referenced to the corresponding CCCl3 (7.26) and CDCl3 
peaks (77.0) ppm. The enantiomeric (or diastereomeric) excesses were determined by 
chiral-stationary phase HPLC employing variable mixtures of n-hexane-isopropanol. 
The conformational spaces of the diastereoiosomers were explored using the 
Monte Carlo torsional procedure as implemented in the Macromodel 9.1 software 
package using the MMFF94 force field. The lowest MMFF94 energy structures were 
refined at the RI
22
-DFT BP86 level using the defbas-1 basis set 
23
 ( QuickOpt option in 
ORCA package) and the def2-TZV auxiliary basis set.
24
 Chemical shifts were computed 
at the IGLO 
25
 RI-OPBE 
26
/pcS-1 
27
 level for the lowest energy DFT optimized 
conformation of each diastereoisomer. The SV/J auxiliary basis set was employed for 
density fitting. Solvation was taken into account using the COSMO model.
28
 The 
computed shieldings were transformed into chemical shifts by computing shieldings for 
the tetramethysilane and benzene molecules at the same level of theory. The 
benzazepine aromatic protons were reference according to benzene shielding whereas 
the rest of protons were reference to TMS. The shifts were computed according to the 
relationship: 
d calc =
s ref -s calc
1-s ref
 
where σref and σcalc are the shieldings computed for the reference proton nuclei and the 
proton of interest in the benzodiazepine. All computations were performed using the 
Orca 2.9 software package.
29
 
 
General procedure for the one-pot synthesis of 1,4-benzodiazepin-2-ones 6-
9. A mixture of the carbonyl compound (1.0 mmol), the amine (1.3 mmol), the 
isocyanide (1.0 mmol) and the protected aminoacid (1.0 mmol) in MeOH (3 mL) was 
submitted to orbital stirring at room temperature for 48–72 h. After completion of the 
reaction, CH2Cl2 (3 mL) and PS-p-TsOH (2.0 mmol) were added. The reaction mixture 
was submitted to orbital stirring at room temperature until complete consumption of the 
unreacted isocyanide (30–60 min). The polymeric reagent was filtered off and 
successively washed [2 times (4 mL)] with MeOH, AcOEt and CH2Cl2. Evaporation of 
the solvents from the filtrate afforded a residue, which was treated with 20% TFA in 
DCE (and heated to 60ºC for 1h). The obtained solution was then treated with saturated 
NaHCO3. After extraction with ethyl acetate, the organic phase was dried (Na2SO4) and 
evaporated under reduced pressure to afford an oily residue that was purified by 
chromatographic methods on silica gel using hexane/AcOEt mixtures. 
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